T1	Participants 45 95	anemic cancer patients on combination chemotherapy
T2	Participants 109 138	Patients with advanced cancer
T3	Participants 409 425	cancer patients.
T4	Participants 823 923	patients with advanced cancer who were receiving myelosuppressive chemotherapy (excluding cisplatin)
T5	Participants 944 1012	153 anemic cancer patients receiving cyclic combination chemotherapy
T6	Participants 1734 1754	rHuEPO-treated group
T7	Participants 1787 1808	placebo-treated group
T8	Participants 2227 2250	rHuEPO-treated patients
T9	Participants 2265 2289	placebo-treated patients
T10	Participants 2337 2360	rHuEPO-treated patients
T11	Participants 2661 2681	rHuEPO-treated group
